Proprietary resveratrol in tests
This article was originally published in The Tan Sheet
Executive Summary
Sirtris Pharmaceuticals' SRT501 resveratrol-containing drug was safe, well-tolerated and "significantly" lowered glucose in an oral glucose tolerance test conducted as part of a 28-day Phase 1b clinical study in patients with type 2 diabetes, which is the first human study of the drug, the Cambridge, Mass.-based biopharmaceutical firm says Jan. 7. The study was designed to assess the safety, tolerability and pharmacokinetics of once-daily, orally administered doses of 2.5 g or 5 g of SRT501, which contains the firm's proprietary resveratrol substance, in type 2 diabetes patients. Pharmacokinetic levels, a measure of drug levels in the blood, were identical at days one and 28, suggesting no drug accumulation. SRT501 showed a statistically significant improvement in an oral glucose tolerance test on day 28 at two hours and a trend toward lower fasting plasma glucose levels. Natural resveratrol is a phytoalexin found in the skin of red grapes and is generating interest as a supplement ingredient (1"The Tan Sheet" Nov. 26, 2007, p. 13)...